HJC0350 is primarily utilized in research settings as a potent and selective inhibitor of the enzyme cyclin-dependent kinase 9 (CDK9). Its application is significant in studying cellular processes such as transcription regulation, apoptosis, and cell cycle control. Researchers employ HJC0350 to investigate its effects on cancer cells, particularly in understanding its potential to inhibit tumor growth by disrupting CDK9-mediated transcription. This makes it a valuable tool in preclinical studies aimed at developing targeted cancer therapies. Additionally, it is used to explore its role in viral replication, as CDK9 is involved in the transcription of certain viruses, offering insights into antiviral drug development.